Healthcare Providers and Services
Company Overview of Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. provides cancer treatment and research services for adults and children in the United States. It offers adult treatment and care services for blood, breast, cutaneous/skin, gastrointestinal, genitourinary, gynecological, head and neck, hematology, melanoma, neuro-oncology, sarcoma, and thoracic cancer; and cancer genetics and prevention services. The company also provides treatment and care for children with cancer, such as blood diseases, bone and soft tissue tumors, brain tumors, histiocytosis, Hodgkin lymphoma, kidney tumors, leukemia, neuroblastoma, non-Hodgkin lymphoma, and rare tumors program. In addition, it offers training in cancer treatment and re...
450 Brookline Avenue
Boston, MA 02215-5450
Founded in 1947
Key Executives for Dana-Farber Cancer Institute, Inc.
Chief Executive Officer and President
Chief Financial Officer and Assistant Treasurer
Chief Operating Officer and Executive Vice President
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2014.
Dana-Farber Cancer Institute, Inc. Key Developments
Dana-Farber Cancer Institute, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015
Feb 22 15
Dana-Farber Cancer Institute, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Presentation Date & Speakers: Feb-23-2015, Barrett J. Rollins, MD, PhD, Chief Scientific Officer, O. Prem Das, Chief Business Development Officer.
Dana-Farber Cancer Institute, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
Dana-Farber Cancer Institute, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Dana-Farber Cancer Institute and Astellas Announce Research Collaboration
Nov 4 14
Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer. K-Ras is the most commonly mutated oncogene in human cancers, with about 30% of all cancers harbouring activating rasmutations. Furthermore, cancers with a high prevalence of K-Ras mutations, such as lung cancer and pancreatic cancer, are difficult to treat and clinical outcomes are poor even with aggressive medical interventions. Despite more than 20 years of research by industry and academia, K-Ras has proven highly difficult to target and no effective therapy currently exists.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|